Literature DB >> 17415311

Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.

Ying Ying Leung1, Kam Shing Tang, Chiu Chi Tsang, Chi Kin Chan, Kwan Keung Wong, Alex Wai-yin Yu.   

Abstract

We report a case of pulmonary hypertension presenting with sudden cardiac arrest, hyperthyroidism and fenfluramine usage. This fatal case of pulmonary hypertension and valvular heart disease is associated with the use of an anorectic drug that had been withdrawn from the market more than eight years ago. Clinicians should alert to the side effects of appetite suppressant and slimming agents. The association between pulmonary hypertension in relation to hyperthyroidism and fenfluramine usage is reviewed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17415311      PMCID： PMC1868350     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


  15 in total

1.  Pulmonary hypertension caused by Graves' thyrotoxicosis: normal pulmonary hemodynamics restored by (131)I treatment.

Authors:  I A Nakchbandi; J A Wirth; S E Inzucchi
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

2.  Hyperthyroidism and pulmonary hypertension.

Authors:  R Thurnheer; R Jenni; E W Russi; P Greminger; R Speich
Journal:  J Intern Med       Date:  1997-08       Impact factor: 8.989

3.  Valvular heart disease associated with fenfluramine-phentermine.

Authors:  H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff
Journal:  N Engl J Med       Date:  1997-08-28       Impact factor: 91.245

4.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

Authors:  L Abenhaim; Y Moride; F Brenot; S Rich; J Benichou; X Kurz; T Higenbottam; C Oakley; E Wouters; M Aubier; G Simonneau; B Bégaud
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

5.  Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction.

Authors:  E K Weir; H L Reeve; J M Huang; E Michelakis; D P Nelson; V Hampl; S L Archer
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

6.  Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.

Authors:  K E Volmar; G M Hutchins
Journal:  Arch Pathol Lab Med       Date:  2001-12       Impact factor: 5.534

7.  Hyperthyroidism and pulmonary hypertension.

Authors:  M Marvisi; M Brianti; G Marani; R Del Borello; M L Bortesi; A Guariglia
Journal:  Respir Med       Date:  2002-04       Impact factor: 3.415

8.  Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine.

Authors:  Tatsuo Tomita; Qiong Zhao
Journal:  Chest       Date:  2002-02       Impact factor: 9.410

Review 9.  Primary pulmonary hypertension.

Authors:  S P Gaine; L J Rubin
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

Review 10.  Primary pulmonary hypertension associated with the use of fenfluramine derivatives.

Authors:  G Simonneau; M Fartoukh; O Sitbon; M Humbert; J L Jagot; P Hervé
Journal:  Chest       Date:  1998-09       Impact factor: 9.410
View more
  1 in total

1.  Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells.

Authors:  Weijuan Yao; Wenbo Mu; Amy Zeifman; Michelle Lofti; Carmelle V Remillard; Ayako Makino; David L Perkins; Joe G Garcia; Jason X J Yuan; Wei Zhang
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.